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Abstract
Background: Society is failing in its moral obligation to improve the standard of healthcare provided to vulnerable
populations, such as people who lack decision making capacity, by a misguided paternalism that seeks to protect
them by excluding them from medical research. Uncertainties surround the basis on which decisions about
research participation is made under dual regulatory regimes, which adds further complexity. Vulnerable individuals’
exclusion from research as a result of such regulation risks condemning such populations to poor quality care as a
result of ‘evidence biased’ medicine.
Main Text: This paper explores the research regulation provisions for proxy decision making for those unable to
provide informed consent for themselves, and the subsequent legal and practical difficulties for decision-makers.
There are two separate regulatory regimes governing research involving adults who lack capacity to consent in
England and Wales. The Mental Capacity Act 2005 governs how incapacitated adults can be involved in research,
however clinical trials of medicinal products are separately regulated by the Medicines for Human Use (Clinical
Trials) Regulations 2004. There are significant differences under these dual regimes in the provisions for those
lacking capacity to participate in medical research. The level of risk permitted differs, with a greater requirement for
justification for participation in a clinical trial than other types of research. Who acts as proxy decision maker, how
much information is provided to the person lacking capacity, and whether they retain the power of veto also
significantly differs.
Conclusion: The development of two separate regulatory regimes has resulted in significant differences between
the provisions for clinical trials and other forms of research, and from usual medical practice. The resulting
uncertainty has reinforced the tendency of those approving and conducting research to exclude adults lacking
capacity to avoid difficult decisions about seeking consent for their participation. Future developments, such as the
incoming EU Regulations, may address some of these differences, however the justification and level of risk
permitted requires review to ensure that requirements are appropriate and proportionate to the burdens and risks
for the individual, and also to the benefits for the wider population represented.
Abbreviations: CTIMP, Clinical trial of an investigational medicinal product; CTR, Medicines for human use (Clinical
trials) regulations 2004; MCA, Mental capacity Act 2005
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Background
Vulnerable populations in society, such as adults lacking
mental capacity to make decisions for themselves, are
routinely denied the opportunity to participate in health-
related research [1–3]. Individuals may lack capacity as a
result of a range of cognitive disorders or conditions,
which may result in the inability of individuals to protect
themselves by freely given informed consent. It has re-
cently been proposed that there are two central, norma-
tively opposed, ethical and legal problems relating to
research involving vulnerable populations: that those un-
able to provide consent are entitled to special protection
as they are unable to adequately protect themselves from
exploitation; however if all those not having capacity to
consent were excluded from research then medicines
and other health interventions would remain untested in
the target population [2]. Vulnerable groups are entitled
to special protection in medical research as, historically,
appalling ethical transgressions have resulted from the
pursuit of scientific data which have often involved vul-
nerable individuals [4].
However concerns regarding the ethical and legal is-
sues of informed consent by people who lack decision-
making capacity as a result of cognitive impairment have
been identified as barriers to participation in medical re-
search [1, 5, 6]. Leading to claims that society is failing in
its moral obligation to improve the standard of evidence-
based healthcare provided to vulnerable populations, who
are currently substantially disadvantaged by the tendency
by research regulatory frameworks (and those that imple-
ment them) to protect them by excluding them from
medical research [2, 4, 7]. Honouring this obligation re-
quires a shift towards offering better protection by includ-
ing them in more research projects, thereby allowing
vulnerable populations to benefit from medical progress.
There have been recent developments to address the
exclusion of some vulnerable groups. The European
Medicines Agency, describing ‘evidence biased medicine’
as a global issue, has developed a Geriatric Medicines
Strategy to ensure the availability of safe and effective
medicines for an ageing population [8]. However, there
have been calls for a more fundamental step change
from the current legal and ethical position of ‘protection
by exclusion’ to ‘protection by inclusion’, through shift-
ing the emphasis of clinical research to the benefit of
vulnerable populations [2].
Adults considered vulnerable require different decision-
making processes for participating in a clinical trial than
decisions made in usual medical care, and also regarding
participation in other types of research. There are two sep-
arate regulatory regimes governing research involving
adults who lack capacity to consent in England and Wales.
The Mental Capacity Act (MCA) 2005 governs how inca-
pacitated adults can be involved in research [9], though it
excludes clinical trials of investigational medicinal prod-
ucts (CTIMPs). Clinical trials involving adults who lack
capacity are separately regulated by the Medicines for
Human Use (Clinical Trials) Regulations 2004 (CTR) [10].
Although there are some similarities between the two
regimes, there are significant differences. Research pro-
jects are classified as CTIMP or non-CTIMP studies–with
some larger research programmes incorporating both,
such as a pre-clinical trial observational stage to ascertain
prevalence of a particular condition, followed by a clinical
trial to evaluate a proposed medical treatment or regime.
The same research site, treating clinicians and participants
may be involved in both stages but different regulatory
frameworks, and hence different decision making pro-
cesses, will apply.
This special treatment presents difficulties for those
involved in the day to day care of adults lacking capacity
who are familiar with the processes for making treat-
ment decisions with this population, but are concerned
about decisions regarding their participation in research
[7]. The complexity of the current legal framework, its
legislative differences, and uncertainty surrounding their
interpretation, has resulted in confusion both for re-
searchers and Research Ethics Committees [11], as well
as clinicians, relatives, and carers involved in decisions
about people participating in research [7]. This issue re-
mains one to be addressed and, unless it is done so,
strategies introduced to improve the inclusion of vulner-
able adults in medical research may fail. This will per-
petuate the current inequitable position where, for
example, older people receive poorer levels of care than
younger people with the same conditions [12]. Even
within the older adult population, there is significant
aged heterogeneity in health status from the relatively fit
to the most frail, which limits the generalisation of
already complex prescribing decisions [13]. The most
vulnerable and frail have limited physiological reserve,
reduced homoeostasis, dysregulations in immune and
inflammation mechanisms, multiple comorbidities, and
polypharmacy [14]. Further robust data about the risks
and benefits of drugs in such populations–particularly
the vulnerable and frail-is urgently needed [15].
This paper explores the differences between the two
regulatory regimes and its impact on the exclusion of
adults who may lack decision-making capacity from
medical research participation.
Discussion
Scientific necessity for inclusion
The scientific validity of research cannot be justified if
the expected benefits are extrapolated from the data ob-
tained from other populations as differences between
populations such as differences in physiology, pharmaco-
kinetics and treatment responsiveness can be significant
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[16]. The importance of inclusion in medical research
is a feature of national health research strategies and
European and International initiatives [17], including the
new EU clinical trials regulation which emphasises the im-
portance of trial relevance [18] and comes into application
in 2018. The new Regulation states that, unless otherwise
justified in the research protocol, the subjects participating
in a clinical trial should represent the population groups,
for example gender and age groups, that are likely to use
the medicinal product investigated in the clinical trial [18].
The Regulation also states that, currently, many trials are
carried out in patient populations which do not necessar-
ily reflect the diversity of the population group on which
the drug will ultimately be used [18].
Inequity of inappropriate exclusion
Those unable to give informed consent for themselves
are often excluded from participating as a result of mis-
guided paternalism and a desire to protect them from
potential harms [19]. Concerns about the inclusion of
vulnerable people are characterised by the much-cited
views of Hans Jonas in the 1960’s that ‘The afflicted
should not be called upon to bear additional burden and
risk [involved in medical research], …they are society’s
special trust and the physician’s particular trust-these are
elementary responses of our moral sense’ [20]. However
it can be argued that the very nature of their affliction
places an increased imperative on the medical commu-
nity and the wider society to search for ways of improv-
ing their plight.
Participation in research can sometimes bring direct
benefits for participants, in terms of enhanced monitor-
ing of their health or access to treatment not widely
available outside a research programme. Excluding such
groups, who may already experience health inequalities,
from participating in research denies them the benefits
that participation can bring and unfairly discriminates
against them [21]. As the inverse research law proposes,
those in the greatest need of research attention are those
least likely to be the subject of research. To deny groups
the benefits of medical research by unduly cautious
regulation is considered to be ‘neither kind not caring
but irresponsible’ by condemning such populations to
poor quality care [22]. Kopelman goes further, claiming
that the practice of routinely excluding vulnerable
groups from research as a result of such regulation is lit-
erally ‘protecting them to death’ [23].
Current research regulation
Adults are presumed to have capacity to make autono-
mous decisions about themselves unless proven other-
wise [9]. The uncertainty regarding the legality of the
inclusion of individuals lacking capacity has been clari-
fied to some extent by the enactment of the MCA,
which has particular provisions relating to research involv-
ing such individuals, although only to research that is not
a clinical trial of a medical product [10]. These are regu-
lated separately under the Clinical Trials Directive [24]
and implemented in the UK by the Clinical Trials Regula-
tions (CTR) [10]. However, there are significant differences
under these two separate regulatory regimes in the provi-
sions for those lacking capacity to participate in medical
research (Table 1). These differences increase the burden
on researchers and clinicians responsible for recruiting eli-
gible participants which presents additional barriers to
conducting research with vulnerable groups [25].
Justification for inclusion–‘minimal risk versus no risk’
Research Ethics Committees have a statutory responsi-
bility for reviewing research proposals involving human
subjects which are categorised as intrusive and, if satis-
fied that the project meets the criteria, will issue ethical
approval. In order for adults lacking capacity to partici-
pate in non-clinical trial research it must be connected
with an impairing condition in the functioning of the
mind or brain affecting the person (or its treatment),
which causes or contributes to the impairment [9]. This
requirement has been particularly challenging in situa-
tions where the research may not be directly connected
to the impairing condition, but the impairment may be a
risk factor for the condition under investigation [1].
Where the research is a clinical trial, the inclusion of
adults lacking capacity is permitted only if the risks and
inconveniences have been weighed against the anticipated
benefits for the individual trial subject and future patients
and that the benefits justify the risks. The clinical trial
must relate directly to a life-threatening or debilitating
condition clinical condition from which the person suffers
and there must be grounds for expecting that administer-
ing the product will produce a benefit to the person out-
weighing the risks or produce no risk at all [10].
There is therefore a greater requirement for justifica-
tion for participation in a clinical trial than other types
of research. This additional justification required can im-
pact on the ability to conduct clinical trials with vulner-
able populations [26] by focussing on the classification
of the intervention alone, rather than a proportionate
and appropriate risk-based assessment of the research
design itself [27]. The requirement that it is expected
that the person themselves will either benefit from the
product outweighing the risks or produce no risk at all is
one of the problematic requirements. In order for this to
be met, there must be an expectation that the product be-
ing tested is either entirely without risk, which is unlikely
for any treatment, or is better than the standard treatment
the person would have received. However clinical trials,
especially in populations such as these, are often urgently
required because existing standard treatments are being
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used despite the lack of evidence of its risks or benefits for
these populations. At present there is little known about
how some drugs commonly used in legally competent
adults, such as anti-psychotics and anti-convulsants, affect
those who may lack competence. There may be significant
differences between those with and without capacity and
the risks and benefits may be different for each group
[26]. An example is individuals with Down’s syndrome,
which is associated with a significantly higher risk of de-
veloping Alzheimer’s disease, who may have an atypical
response to anti-dementia medication compared to other
individuals and may experience a difference in disease
progression than the general population [22]. In such situ-
ations the safety and efficacy of medicines for these groups
needs to be established through a clinical trial which may
involve individuals who, despite all reasonable attempts to
enable them to provide consent for themselves, are found
to lack capacity.
The Declaration of Helsinki [17] does not stipulate a
limit for the degree of risk that may be permitted, but
does require that the research must be justified by its
potential value for future care. The incoming EU Regula-
tions [18], adopted on 14th April 2014 and expected to
come into application by October 2018, reflect this pos-
ition by requiring that the trial either confers a direct
benefit to the incapacitated subject, outweighing the risks
and burdens involved; or some benefit for the population
represented by the incapacitated subject concerned if the
clinical trial relates directly to the life-threatening or de-
bilitating medical condition from which the subject suffers
and such trial will pose only minimal risk or burden to the
incapacitated subject concerned when compared with the
standard treatment of their condition.
Who can act as proxy decision maker
The MCA provides for another person to be consulted
for advice before the individual lacking capacity is in-
cluded in the research. If the researcher is unable to
identify a personal consultee who has an unpaid or non-
professional role in caring for the person, they must ap-
point a nominated consultee who may be a healthcare
professional or a nominated individual working for a
relevant organisation such as a local authority [9].
The consultee must be provided with the information
about the research and is asked whether the participant
would have declined to take part if he or she had capacity
[9] and any indication that they would not have wished to
participate must be respected. Responsibility for deciding
whether to include a person lacking capacity lies ultim-
ately with the researcher. All other decisions relating
Table 1 Differences between provisions for adults lacking capacity under Mental Capacity Act 2005 (MCA) and Medicines for
Human Use (Clinical Trials) Regulations 2004 (CTR)
MCA CTR
Who acts as decision maker Researcher must consult:
Personal consultee-a person who is engaged in caring
for the person or is interested in their welfare, except
as a professional or for remuneration–friend, relative,
unpaid carer, attorney acting under LPA, court
appointed deputy
Nominated consultee-a person who has no connection
with the project-healthcare professional, nominated
individual
Legal representative is a person who, by virtue of their
relationship, is suitable to act as their legal representative
and is available and willing to act.
Personal legal representative–friend, relative.
Professional legal representative–the doctor primarily
responsible for their medical treatment or a person
nominated by their health care provider. Must not be
connected with the trial.
Basis for the decision Consultee asked for advice whether the participant
should take part or would not have wished to
participate. Responsibility whether to include the
participant lies with the researcher
Informed consent given by the legal representative
represents their presumed will. Representative to decide
whether the participant would have wanted to participate
had they capacity to do so.
Provision of information Does not specify any provisions that the person has
to be informed about the research once they have
been assessed as lacking capacity
Person lacking capacity must have received information
about the trial, its risks and benefits, according to his or
her capacity before they can be involved.
Dissent/objection Weight is given to any refusal or dissent from the
individual lacking capacity, even when the person has
little or no ability to understand the situation. If the
person indicates (in any way) that he wishes to be
withdrawn from the project he must be withdrawn
without delay.
The explicit wish of a subject who is capable of forming
an opinion and assessing the information to refuse
participation in, or to be withdrawn from, the clinical trial
at any time must be considered by the investigator
Level of risk permitted Research must be connected with an impairing
condition in the functioning of the mind or brain
affecting the person, or its treatment. There must be
reasonable grounds for believing that the risk to the
person is negligible and that anything done in relation
to the person will not interfere with their freedom
of action or privacy in a significant way or be unduly
invasive or restrictive.
The clinical trial must relate directly to a life-threatening or
debilitating condition clinical condition from which the
person suffers. There must be grounds for expecting that
administering the product will produce a benefit to the
person outweighing the risks or produce no risk at all
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to medical treatment and care made on behalf of an
adult who lacks capacity are covered by the MCA
provisions, generally under ‘best interests’ processes.
This results in uncertainty and reluctance when deci-
sions regarding the participation of such individuals
in research are being made.
In clinical trials, when the person is not capable of giv-
ing consent, informed consent is given by his or her
legal representative [10]. However the provision of in-
formed consent by proxy, rather than simply advice as
stated under the MCA, has been considered as a land-
mark shift in medical law. Previously the position under
the common law was that, even where an adult patient
lacked the mental capacity (either temporarily or per-
manently) to give or withhold consent for themselves,
no-one else could give consent on their behalf. This ex-
ceptional consent by proxy is problematic for health pro-
fessionals involved in decision making but inexperienced
in conducting research involving adults lacking capacity.
Thus the MCA gives the consultee a right of veto but
not a right to give their consent, in contrast to the regu-
lations for a clinical trial of a medicinal product where
consent by proxy is given. These differences are not
widely understood and can be a source of confusion
amongst regular care givers for those lacking capacity
who are familiar with other decision making processes,
such as through best interests meetings.
Basis for the decision
A core principle of the MCA is that all decisions and ac-
tions must be in the best interests of the person lacking
capacity [9]. However, best interest decisions do not
apply when considering the involvement of someone
who lacks capacity in research, which involves a different
process and criteria. The researchers must seek advice
regarding whether the person should take part in the
project, and what, in his opinion, their wishes and feel-
ings about taking part in the project would be likely to
be if they had capacity in relation to the matter [9].
Where the individual acting as a consultee has other
moral, professional or legal obligations towards the per-
son lacking capacity, they may have a prevailing obliga-
tion to protect their best interests. Therefore, in addition
to establishing what the person’s wishes and feelings
about taking part in the project would be likely to be if
they had capacity, the basis for this proxy or surrogate
decision-making may involve a consideration of their
best interests. However ‘best interests’ has been argued
to be an ethically weak basis for decision making in
medical research for those lacking capacity as, whilst
there may be future benefit from the medical knowledge
obtained, there may no direct benefit to the participant
[28]. Indeed, it has been suggested that medical research
‘can never be primarily in a patient’s best interests’ [29]
but intended to benefit both future persons and the
common good [28]. It is unclear how this best interests
obligation can be balanced against any conflicting advice
about the person’s wish to participate. The relative weight
given to any assent or dissent/refusal from the person, bal-
anced against any advance decision (a ‘living will’) previ-
ously made by the person, is unclear. Although nothing
may be done to the person in the course of the research
which would be contrary to any advance decisions by
them which has effect [9].
In clinical trials, the legal representative must decide
whether the person lacking capacity should participate
in the trial on the basis of what they would have wanted
had they the capacity to choose for themselves, their
presumed will. They need only consider, not necessarily
respect, the person’s actual wishes on the day, even if
they dissent. This decision is not based on the person’s
best interests and it is unclear how the legal representa-
tive can presume another’s will, given that there may be
little or no evidence of their intent, without it being a
form of substituted judgement. The adult lacking cap-
acity may never have had decision making capacity at
any point. These difficulties become even greater when
the relationship between the person lacking capacity and
the legal representative becomes more distant. The CTR
provides that, where a personal representative cannot be
found, a ‘professional’ representative may be sought by the
researchers. This person, usually another doctor, may
know nothing about the wishes of the patient concerned
and may not have been involved in their care at a time
when they had capacity.
The incoming EU Regulations has left a wide margin
for the application of consent by proxy, by leaving the
Member States to determine the legally designated rep-
resentatives of incapacitated persons and minors [18].
Requirement for provision of information
The level of information required to be provided to the
person who lacks capacity is different for those involved
in a clinical trial from those participating in other forms
of research. Whilst the MCA does not specify any provi-
sions that the person has to be informed about the re-
search once they have been assessed as lacking capacity
[9], the CTR requires that the person lacking capacity
must have received information about the trial, its risks
and benefits according to his or her capacity before they
can be involved [10].
Dissent or power of veto
There are differences in the weight given to any assent
or dissent from the person lacking capacity between the
legislation concerning clinical trials and that governing
other forms of research. Under the MCA much weight
is given to any refusal or dissent from the individual
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lacking capacity, even when the person has little or no
ability to understand the situation. Section 33 of the
MCA states that if the person indicates (in any way) that
he wishes to be withdrawn from the project he must be
withdrawn without delay [9]. It clearly indicates that any
objection is considered a veto but does not specify any
conditions, such as informing the patient according to
their level of understanding, and is in sharp contrast to
the provisions for clinical trials. Under the CTR the per-
son unable to give informed consent must have received
information about the trial according to his/her capacity.
However the explicit wish of a subject capable of asses-
sing this information and forming an opinion refuses to
participate must only be considered by the investigators
[10]. Whilst any appropriately informed dissent must be
considered by the investigator, it does not have to be
respected when ultimately deciding the matter. As a re-
sult, in a clinical trial a patient’s wishes need only be
considered, however these wishes must at least be in-
formed to some extent.
Thus the CTR appear to protect the person’s current
wishes less vigorously than the MCA, despite requiring
the provision of more information and a more active en-
dorsement on the part of the subject [30]. Despite the
emphasis on the provision of information to the person
lacking capacity, there is no requirement to seek the
agreement of the person; assent is considered to be the
mere absence of an objection.
Addressing the imbalance
The requirement for a clinical trial to relate directly to a
life-threatening or debilitating condition clinical condi-
tion from which the person lacking capacity suffers is
particularly problematic. Adults lacking capacity may be
at high risk of developing conditions as a result of the
physiological frailty and vulnerability that may accom-
pany cognitive impairment, but may not currently suffer
from the condition under investigation. Additionally, the
condition being investigated may not ‘cause or contrib-
ute to’ the impairing condition, but may be a conse-
quence of that condition, such as aspiration pneumonia.
Commonly, new interventions are sought to reduce the
risk of vulnerable individuals developing such conditions.
If the proposed intervention is a medicinal product there
must be grounds for expecting that administering the
product will produce a benefit to the person outweighing
the risks or produce no risk at all [10], which may be
problematic in placebo-controlled randomised trials.
However the benefits and risks cannot be ascertained
without rigorous clinical trials in the population most at
risk of the condition. The benefits and risks in a healthier
cohort, even of similar age profile, will materially differ.
Existing treatments and interventions, and indeed the
condition itself, will already pose accompanying risks. The
risks which may accompany research participation need
to be balanced against the harms which may result
from the use of existing treatment which has not been
properly evaluated in the practice population. Non-
CTIMPs already permit a ‘negligible’ risk to the person
[10], and incoming clinical trial regulations allow a
minimal risk or burden when compared to the standard
treatment for their condition [20]. It has also intro-
duced the concept that such risks may be justified by
the potential value for the future care of the wider
population the person lacking capacity represents, in
line with the Declaration of Helsinki [17].
There is an opportunity for those responsible for re-
search approval and governance, as well as clinicians,
relatives, and carers involved in decisions about people
participating in research, to review whether the interests
of people who lack capacity are best served by excluding
them from the improvements in care that only research
can demonstrate are safe and effective. The level of risk
permitted for all types of research, the requirement for
provision of information, and the power of veto or
dissent however uninformed should be more closely
aligned in order to harmonise and simplify processes
and therefore address the current imbalance.
Conclusions
Medical research is essential to improve healthcare for
all members of society. Those individuals or groups in
society who are considered vulnerable must have equit-
able access and opportunity to participate in research as
all other groups. Actively seeking the involvement of
marginalised groups upholds ethical principles by ensur-
ing that the benefits of research are distributed widely
across society, and by seeking to improve health care
both for the individual concerned and the group they
represent. These groups already experience health dis-
parities, which will persist indefinitely unless research
into the conditions and specific treatments that affect
these individuals is supported. Vulnerable people com-
monly have complex health care needs, but may experi-
ence poorer levels of care and higher levels of adverse
effects from medication use than their cognisant coun-
terparts. However involving vulnerable people in medical
research, particularly those with cognitive impairment, is
problematic.
Research involving vulnerable groups, such as adults
lacking capacity, raises many ethical and legal issues:
particularly with respect to informed consent for them
to be included in a project. The current legal position is
that adults lacking capacity are excluded from medical
research unless their inclusion can be amply justified.
However this position, rather than a requirement for
their exclusion to be justified, conflicts with the moral
obligation to improve evidence-based health care for
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all–particularly those with the highest health care needs
and most vulnerable to adverse events.
Where an individual is unable to provide informed
consent for themselves, alternative arrangements for
proxy decision making exist. The development of two
separate regulatory regimes has resulted in significant
differences between the regulatory approaches to clinical
trials and other forms of research, and from usual med-
ical practice. The level of risk permitted differs, with a
greater requirement for justification for participation in
a clinical trial than other types of research. Who acts as
proxy decision maker, how much information is pro-
vided to the person lacking capacity, and whether they
retain the power of veto also significantly differs. As a
result, there is uncertainty about the involvement of
adults lacking capacity in different types of research, and
the provisions and interpretation of different regulations.
These complexities have led to uncertainty about their
inclusion, which reinforces the tendency by those ap-
proving and conducting research to exclude them in
order to avoid difficult decisions about seeking consent
for their participation.
Future developments, such as the incoming EU Regula-
tions, may address some of these differences, however at
present adults lacking capacity are treated differently from
other groups and experience inequality and less innovation
in their medical care and treatment, as a result. In order to
redress the current ageist ‘evidence bias’, the impact of re-
search regulation must be addressed. The justification and
level of risk permitted for participating in research requires
review to ensure that requirements are appropriate and
proportionate to the burdens and risks for the individual
and also to the benefits for the wider population repre-
sented. Widespread exclusion from participation in re-
search carries intrinsic risks for vulnerable groups, as they
may be denied access to novel treatments or new preventa-
tive interventions, and existing treatments may remain
largely untested in this population.
Further research is needed to explore caregivers’
attitudes and knowledge of the legal basis for decision-
making, and to evaluate the impact of the current regu-
latory regimes on conducting research with vulnerable
populations. The provision of information and any power
of veto or dissent should be harmonised and simplified in
order to redress the current imbalance. Comprehensive
guidance is urgently needed for clinicians, relatives, and
carers involved in decisions about people participating in
research. Information about balancing best interests, pre-
sumed will and advance decisions is required to support
decision-makers whilst adequately protecting vulnerable
groups. Fundamentally, a shift must be made away from
misguided protectionism, and towards promoting appro-
priate inclusion of adults lacking capacity in order to
honour society’s obligation for equitable health care for all.
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